Narayana Hrudayalaya Limited
Narayana Hrudayalaya Limited (NH.NS) Stock Competitors & Peer Comparison
See (NH.NS) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Care Facilities Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| NH.NS | ₹1,625.00 | -0.62% | 330B | 42.47 | ₹38.26 | +0.28% |
| APOLLOHOSP.NS | ₹7,317.50 | +0.16% | 1.1T | 58.36 | ₹125.38 | +0.26% |
| APOLLOHOSP.BO | ₹7,316.35 | +0.16% | 1.1T | 58.28 | ₹125.54 | +0.26% |
| MAXHEALTH.BO | ₹944.70 | -1.40% | 919.3B | 65.06 | ₹14.52 | +0.16% |
| MAXHEALTH.NS | ₹944.60 | -1.49% | 919.2B | 65.01 | ₹14.53 | +0.16% |
| FORTIS.BO | ₹788.80 | -0.72% | 595.5B | 62.06 | ₹12.71 | +0.13% |
| FORTIS.NS | ₹788.75 | -0.79% | 595.5B | 62.01 | ₹12.72 | +0.13% |
| ASTERDM.BO | ₹658.90 | -4.22% | 340.6B | 103.28 | ₹6.38 | +0.56% |
| ASTERDM.NS | ₹658.10 | -4.33% | 340.2B | 102.35 | ₹6.43 | +0.56% |
| NH.BO | ₹1,624.10 | -0.72% | 329.9B | 39.08 | ₹41.56 | +0.28% |
Stock Comparison
NH.NS vs APOLLOHOSP.NS Comparison April 2026
NH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NH.NS stands at 330B. In comparison, APOLLOHOSP.NS has a market cap of 1.1T. Regarding current trading prices, NH.NS is priced at ₹1,625.00, while APOLLOHOSP.NS trades at ₹7,317.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NH.NS currently has a P/E ratio of 42.47, whereas APOLLOHOSP.NS's P/E ratio is 58.36. In terms of profitability, NH.NS's ROE is +0.21%, compared to APOLLOHOSP.NS's ROE of +0.21%. Regarding short-term risk, NH.NS is less volatile compared to APOLLOHOSP.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NH.NS.Check APOLLOHOSP.NS's competition here
NH.NS vs APOLLOHOSP.BO Comparison April 2026
NH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NH.NS stands at 330B. In comparison, APOLLOHOSP.BO has a market cap of 1.1T. Regarding current trading prices, NH.NS is priced at ₹1,625.00, while APOLLOHOSP.BO trades at ₹7,316.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NH.NS currently has a P/E ratio of 42.47, whereas APOLLOHOSP.BO's P/E ratio is 58.28. In terms of profitability, NH.NS's ROE is +0.21%, compared to APOLLOHOSP.BO's ROE of +0.21%. Regarding short-term risk, NH.NS is less volatile compared to APOLLOHOSP.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NH.NS.Check APOLLOHOSP.BO's competition here
NH.NS vs MAXHEALTH.BO Comparison April 2026
NH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NH.NS stands at 330B. In comparison, MAXHEALTH.BO has a market cap of 919.3B. Regarding current trading prices, NH.NS is priced at ₹1,625.00, while MAXHEALTH.BO trades at ₹944.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NH.NS currently has a P/E ratio of 42.47, whereas MAXHEALTH.BO's P/E ratio is 65.06. In terms of profitability, NH.NS's ROE is +0.21%, compared to MAXHEALTH.BO's ROE of +0.15%. Regarding short-term risk, NH.NS is less volatile compared to MAXHEALTH.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NH.NS.Check MAXHEALTH.BO's competition here
NH.NS vs MAXHEALTH.NS Comparison April 2026
NH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NH.NS stands at 330B. In comparison, MAXHEALTH.NS has a market cap of 919.2B. Regarding current trading prices, NH.NS is priced at ₹1,625.00, while MAXHEALTH.NS trades at ₹944.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NH.NS currently has a P/E ratio of 42.47, whereas MAXHEALTH.NS's P/E ratio is 65.01. In terms of profitability, NH.NS's ROE is +0.21%, compared to MAXHEALTH.NS's ROE of +0.15%. Regarding short-term risk, NH.NS is less volatile compared to MAXHEALTH.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NH.NS.Check MAXHEALTH.NS's competition here
NH.NS vs FORTIS.BO Comparison April 2026
NH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NH.NS stands at 330B. In comparison, FORTIS.BO has a market cap of 595.5B. Regarding current trading prices, NH.NS is priced at ₹1,625.00, while FORTIS.BO trades at ₹788.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NH.NS currently has a P/E ratio of 42.47, whereas FORTIS.BO's P/E ratio is 62.06. In terms of profitability, NH.NS's ROE is +0.21%, compared to FORTIS.BO's ROE of +0.11%. Regarding short-term risk, NH.NS is less volatile compared to FORTIS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NH.NS.Check FORTIS.BO's competition here
NH.NS vs FORTIS.NS Comparison April 2026
NH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NH.NS stands at 330B. In comparison, FORTIS.NS has a market cap of 595.5B. Regarding current trading prices, NH.NS is priced at ₹1,625.00, while FORTIS.NS trades at ₹788.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NH.NS currently has a P/E ratio of 42.47, whereas FORTIS.NS's P/E ratio is 62.01. In terms of profitability, NH.NS's ROE is +0.21%, compared to FORTIS.NS's ROE of +0.11%. Regarding short-term risk, NH.NS is less volatile compared to FORTIS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NH.NS.Check FORTIS.NS's competition here
NH.NS vs ASTERDM.BO Comparison April 2026
NH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NH.NS stands at 330B. In comparison, ASTERDM.BO has a market cap of 340.6B. Regarding current trading prices, NH.NS is priced at ₹1,625.00, while ASTERDM.BO trades at ₹658.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NH.NS currently has a P/E ratio of 42.47, whereas ASTERDM.BO's P/E ratio is 103.28. In terms of profitability, NH.NS's ROE is +0.21%, compared to ASTERDM.BO's ROE of +0.09%. Regarding short-term risk, NH.NS is less volatile compared to ASTERDM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NH.NS.Check ASTERDM.BO's competition here
NH.NS vs ASTERDM.NS Comparison April 2026
NH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NH.NS stands at 330B. In comparison, ASTERDM.NS has a market cap of 340.2B. Regarding current trading prices, NH.NS is priced at ₹1,625.00, while ASTERDM.NS trades at ₹658.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NH.NS currently has a P/E ratio of 42.47, whereas ASTERDM.NS's P/E ratio is 102.35. In terms of profitability, NH.NS's ROE is +0.21%, compared to ASTERDM.NS's ROE of +0.09%. Regarding short-term risk, NH.NS is less volatile compared to ASTERDM.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NH.NS.Check ASTERDM.NS's competition here
NH.NS vs NH.BO Comparison April 2026
NH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NH.NS stands at 330B. In comparison, NH.BO has a market cap of 329.9B. Regarding current trading prices, NH.NS is priced at ₹1,625.00, while NH.BO trades at ₹1,624.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NH.NS currently has a P/E ratio of 42.47, whereas NH.BO's P/E ratio is 39.08. In terms of profitability, NH.NS's ROE is +0.21%, compared to NH.BO's ROE of +0.21%. Regarding short-term risk, NH.NS is more volatile compared to NH.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NH.NS.Check NH.BO's competition here
NH.NS vs MEDANTA.BO Comparison April 2026
NH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NH.NS stands at 330B. In comparison, MEDANTA.BO has a market cap of 268.9B. Regarding current trading prices, NH.NS is priced at ₹1,625.00, while MEDANTA.BO trades at ₹1,001.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NH.NS currently has a P/E ratio of 42.47, whereas MEDANTA.BO's P/E ratio is 52.30. In terms of profitability, NH.NS's ROE is +0.21%, compared to MEDANTA.BO's ROE of +0.15%. Regarding short-term risk, NH.NS is less volatile compared to MEDANTA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NH.NS.Check MEDANTA.BO's competition here
NH.NS vs MEDANTA.NS Comparison April 2026
NH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NH.NS stands at 330B. In comparison, MEDANTA.NS has a market cap of 268.9B. Regarding current trading prices, NH.NS is priced at ₹1,625.00, while MEDANTA.NS trades at ₹1,000.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NH.NS currently has a P/E ratio of 42.47, whereas MEDANTA.NS's P/E ratio is 52.29. In terms of profitability, NH.NS's ROE is +0.21%, compared to MEDANTA.NS's ROE of +0.15%. Regarding short-term risk, NH.NS is less volatile compared to MEDANTA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NH.NS.Check MEDANTA.NS's competition here
NH.NS vs KIMS.NS Comparison April 2026
NH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NH.NS stands at 330B. In comparison, KIMS.NS has a market cap of 250.6B. Regarding current trading prices, NH.NS is priced at ₹1,625.00, while KIMS.NS trades at ₹626.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NH.NS currently has a P/E ratio of 42.47, whereas KIMS.NS's P/E ratio is 83.28. In terms of profitability, NH.NS's ROE is +0.21%, compared to KIMS.NS's ROE of +0.13%. Regarding short-term risk, NH.NS is more volatile compared to KIMS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NH.NS.Check KIMS.NS's competition here
NH.NS vs KIMS.BO Comparison April 2026
NH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NH.NS stands at 330B. In comparison, KIMS.BO has a market cap of 250.5B. Regarding current trading prices, NH.NS is priced at ₹1,625.00, while KIMS.BO trades at ₹626.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NH.NS currently has a P/E ratio of 42.47, whereas KIMS.BO's P/E ratio is 83.15. In terms of profitability, NH.NS's ROE is +0.21%, compared to KIMS.BO's ROE of +0.13%. Regarding short-term risk, NH.NS is more volatile compared to KIMS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NH.NS.Check KIMS.BO's competition here
NH.NS vs RAINBOW.BO Comparison April 2026
NH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NH.NS stands at 330B. In comparison, RAINBOW.BO has a market cap of 116.8B. Regarding current trading prices, NH.NS is priced at ₹1,625.00, while RAINBOW.BO trades at ₹1,149.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NH.NS currently has a P/E ratio of 42.47, whereas RAINBOW.BO's P/E ratio is 45.55. In terms of profitability, NH.NS's ROE is +0.21%, compared to RAINBOW.BO's ROE of +0.18%. Regarding short-term risk, NH.NS is less volatile compared to RAINBOW.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NH.NS.Check RAINBOW.BO's competition here
NH.NS vs RAINBOW.NS Comparison April 2026
NH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NH.NS stands at 330B. In comparison, RAINBOW.NS has a market cap of 116.7B. Regarding current trading prices, NH.NS is priced at ₹1,625.00, while RAINBOW.NS trades at ₹1,149.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NH.NS currently has a P/E ratio of 42.47, whereas RAINBOW.NS's P/E ratio is 45.54. In terms of profitability, NH.NS's ROE is +0.21%, compared to RAINBOW.NS's ROE of +0.18%. Regarding short-term risk, NH.NS is less volatile compared to RAINBOW.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NH.NS.Check RAINBOW.NS's competition here
NH.NS vs JLHL.BO Comparison April 2026
NH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NH.NS stands at 330B. In comparison, JLHL.BO has a market cap of 81.1B. Regarding current trading prices, NH.NS is priced at ₹1,625.00, while JLHL.BO trades at ₹1,236.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NH.NS currently has a P/E ratio of 42.47, whereas JLHL.BO's P/E ratio is 43.00. In terms of profitability, NH.NS's ROE is +0.21%, compared to JLHL.BO's ROE of +0.14%. Regarding short-term risk, NH.NS is more volatile compared to JLHL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NH.NS.Check JLHL.BO's competition here
NH.NS vs JLHL.NS Comparison April 2026
NH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NH.NS stands at 330B. In comparison, JLHL.NS has a market cap of 80.6B. Regarding current trading prices, NH.NS is priced at ₹1,625.00, while JLHL.NS trades at ₹1,229.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NH.NS currently has a P/E ratio of 42.47, whereas JLHL.NS's P/E ratio is 42.63. In terms of profitability, NH.NS's ROE is +0.21%, compared to JLHL.NS's ROE of +0.14%. Regarding short-term risk, NH.NS is more volatile compared to JLHL.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NH.NS.Check JLHL.NS's competition here
NH.NS vs HCG.BO Comparison April 2026
NH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NH.NS stands at 330B. In comparison, HCG.BO has a market cap of 78.9B. Regarding current trading prices, NH.NS is priced at ₹1,625.00, while HCG.BO trades at ₹528.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NH.NS currently has a P/E ratio of 42.47, whereas HCG.BO's P/E ratio is 403.44. In terms of profitability, NH.NS's ROE is +0.21%, compared to HCG.BO's ROE of +0.02%. Regarding short-term risk, NH.NS is more volatile compared to HCG.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NH.NS.Check HCG.BO's competition here
NH.NS vs HCG.NS Comparison April 2026
NH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NH.NS stands at 330B. In comparison, HCG.NS has a market cap of 78.8B. Regarding current trading prices, NH.NS is priced at ₹1,625.00, while HCG.NS trades at ₹527.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NH.NS currently has a P/E ratio of 42.47, whereas HCG.NS's P/E ratio is 402.82. In terms of profitability, NH.NS's ROE is +0.21%, compared to HCG.NS's ROE of +0.02%. Regarding short-term risk, NH.NS is less volatile compared to HCG.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NH.NS.Check HCG.NS's competition here
NH.NS vs YATHARTH.BO Comparison April 2026
NH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NH.NS stands at 330B. In comparison, YATHARTH.BO has a market cap of 64.9B. Regarding current trading prices, NH.NS is priced at ₹1,625.00, while YATHARTH.BO trades at ₹673.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NH.NS currently has a P/E ratio of 42.47, whereas YATHARTH.BO's P/E ratio is 38.71. In terms of profitability, NH.NS's ROE is +0.21%, compared to YATHARTH.BO's ROE of +0.11%. Regarding short-term risk, NH.NS is less volatile compared to YATHARTH.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NH.NS.Check YATHARTH.BO's competition here
NH.NS vs YATHARTH.NS Comparison April 2026
NH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NH.NS stands at 330B. In comparison, YATHARTH.NS has a market cap of 64.7B. Regarding current trading prices, NH.NS is priced at ₹1,625.00, while YATHARTH.NS trades at ₹671.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NH.NS currently has a P/E ratio of 42.47, whereas YATHARTH.NS's P/E ratio is 38.59. In terms of profitability, NH.NS's ROE is +0.21%, compared to YATHARTH.NS's ROE of +0.11%. Regarding short-term risk, NH.NS is less volatile compared to YATHARTH.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NH.NS.Check YATHARTH.NS's competition here
NH.NS vs KOVAI.BO Comparison April 2026
NH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NH.NS stands at 330B. In comparison, KOVAI.BO has a market cap of 55.8B. Regarding current trading prices, NH.NS is priced at ₹1,625.00, while KOVAI.BO trades at ₹5,097.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NH.NS currently has a P/E ratio of 42.47, whereas KOVAI.BO's P/E ratio is 23.66. In terms of profitability, NH.NS's ROE is +0.21%, compared to KOVAI.BO's ROE of +0.22%. Regarding short-term risk, NH.NS is more volatile compared to KOVAI.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NH.NS.Check KOVAI.BO's competition here
NH.NS vs INDRAMEDCO.BO Comparison April 2026
NH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NH.NS stands at 330B. In comparison, INDRAMEDCO.BO has a market cap of 36.7B. Regarding current trading prices, NH.NS is priced at ₹1,625.00, while INDRAMEDCO.BO trades at ₹400.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NH.NS currently has a P/E ratio of 42.47, whereas INDRAMEDCO.BO's P/E ratio is 20.07. In terms of profitability, NH.NS's ROE is +0.21%, compared to INDRAMEDCO.BO's ROE of +0.31%. Regarding short-term risk, NH.NS is less volatile compared to INDRAMEDCO.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NH.NS.Check INDRAMEDCO.BO's competition here
NH.NS vs INDRAMEDCO.NS Comparison April 2026
NH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NH.NS stands at 330B. In comparison, INDRAMEDCO.NS has a market cap of 36.6B. Regarding current trading prices, NH.NS is priced at ₹1,625.00, while INDRAMEDCO.NS trades at ₹399.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NH.NS currently has a P/E ratio of 42.47, whereas INDRAMEDCO.NS's P/E ratio is 20.02. In terms of profitability, NH.NS's ROE is +0.21%, compared to INDRAMEDCO.NS's ROE of +0.31%. Regarding short-term risk, NH.NS is less volatile compared to INDRAMEDCO.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NH.NS.Check INDRAMEDCO.NS's competition here
NH.NS vs ARTEMISMED.BO Comparison April 2026
NH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NH.NS stands at 330B. In comparison, ARTEMISMED.BO has a market cap of 35.4B. Regarding current trading prices, NH.NS is priced at ₹1,625.00, while ARTEMISMED.BO trades at ₹223.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NH.NS currently has a P/E ratio of 42.47, whereas ARTEMISMED.BO's P/E ratio is N/A. In terms of profitability, NH.NS's ROE is +0.21%, compared to ARTEMISMED.BO's ROE of +0.11%. Regarding short-term risk, NH.NS is less volatile compared to ARTEMISMED.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NH.NS.Check ARTEMISMED.BO's competition here
NH.NS vs ARTEMISMED.NS Comparison April 2026
NH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NH.NS stands at 330B. In comparison, ARTEMISMED.NS has a market cap of 35.3B. Regarding current trading prices, NH.NS is priced at ₹1,625.00, while ARTEMISMED.NS trades at ₹224.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NH.NS currently has a P/E ratio of 42.47, whereas ARTEMISMED.NS's P/E ratio is 97.91. In terms of profitability, NH.NS's ROE is +0.21%, compared to ARTEMISMED.NS's ROE of +0.11%. Regarding short-term risk, NH.NS is less volatile compared to ARTEMISMED.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NH.NS.Check ARTEMISMED.NS's competition here
NH.NS vs KOVAI.NS Comparison April 2026
NH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NH.NS stands at 330B. In comparison, KOVAI.NS has a market cap of 35.3B. Regarding current trading prices, NH.NS is priced at ₹1,625.00, while KOVAI.NS trades at ₹2,581.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NH.NS currently has a P/E ratio of 42.47, whereas KOVAI.NS's P/E ratio is 20.74. In terms of profitability, NH.NS's ROE is +0.21%, compared to KOVAI.NS's ROE of +0.22%. Regarding short-term risk, NH.NS is less volatile compared to KOVAI.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NH.NS.Check KOVAI.NS's competition here
NH.NS vs DRAGARWQ.BO Comparison April 2026
NH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NH.NS stands at 330B. In comparison, DRAGARWQ.BO has a market cap of 22.7B. Regarding current trading prices, NH.NS is priced at ₹1,625.00, while DRAGARWQ.BO trades at ₹4,703.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NH.NS currently has a P/E ratio of 42.47, whereas DRAGARWQ.BO's P/E ratio is 31.87. In terms of profitability, NH.NS's ROE is +0.21%, compared to DRAGARWQ.BO's ROE of +0.30%. Regarding short-term risk, NH.NS is less volatile compared to DRAGARWQ.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NH.NS.Check DRAGARWQ.BO's competition here
NH.NS vs SHALBY.NS Comparison April 2026
NH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NH.NS stands at 330B. In comparison, SHALBY.NS has a market cap of 15B. Regarding current trading prices, NH.NS is priced at ₹1,625.00, while SHALBY.NS trades at ₹139.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NH.NS currently has a P/E ratio of 42.47, whereas SHALBY.NS's P/E ratio is 181.04. In terms of profitability, NH.NS's ROE is +0.21%, compared to SHALBY.NS's ROE of +0.01%. Regarding short-term risk, NH.NS is less volatile compared to SHALBY.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NH.NS.Check SHALBY.NS's competition here
NH.NS vs SHALBY.BO Comparison April 2026
NH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NH.NS stands at 330B. In comparison, SHALBY.BO has a market cap of 14.9B. Regarding current trading prices, NH.NS is priced at ₹1,625.00, while SHALBY.BO trades at ₹138.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NH.NS currently has a P/E ratio of 42.47, whereas SHALBY.BO's P/E ratio is 180.00. In terms of profitability, NH.NS's ROE is +0.21%, compared to SHALBY.BO's ROE of +0.01%. Regarding short-term risk, NH.NS is less volatile compared to SHALBY.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NH.NS.Check SHALBY.BO's competition here
NH.NS vs KMCSHIL.BO Comparison April 2026
NH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NH.NS stands at 330B. In comparison, KMCSHIL.BO has a market cap of 13.6B. Regarding current trading prices, NH.NS is priced at ₹1,625.00, while KMCSHIL.BO trades at ₹83.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NH.NS currently has a P/E ratio of 42.47, whereas KMCSHIL.BO's P/E ratio is 37.36. In terms of profitability, NH.NS's ROE is +0.21%, compared to KMCSHIL.BO's ROE of +0.22%. Regarding short-term risk, NH.NS is less volatile compared to KMCSHIL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NH.NS.Check KMCSHIL.BO's competition here
NH.NS vs MAXINDIA.BO Comparison April 2026
NH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NH.NS stands at 330B. In comparison, MAXINDIA.BO has a market cap of 9.2B. Regarding current trading prices, NH.NS is priced at ₹1,625.00, while MAXINDIA.BO trades at ₹213.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NH.NS currently has a P/E ratio of 42.47, whereas MAXINDIA.BO's P/E ratio is -3560.83. In terms of profitability, NH.NS's ROE is +0.21%, compared to MAXINDIA.BO's ROE of +0.15%. Regarding short-term risk, NH.NS is less volatile compared to MAXINDIA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NH.NS.Check MAXINDIA.BO's competition here
NH.NS vs MAXIND.NS Comparison April 2026
NH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NH.NS stands at 330B. In comparison, MAXIND.NS has a market cap of 7.6B. Regarding current trading prices, NH.NS is priced at ₹1,625.00, while MAXIND.NS trades at ₹144.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NH.NS currently has a P/E ratio of 42.47, whereas MAXIND.NS's P/E ratio is -4.85. In terms of profitability, NH.NS's ROE is +0.21%, compared to MAXIND.NS's ROE of -0.36%. Regarding short-term risk, NH.NS is less volatile compared to MAXIND.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NH.NS.Check MAXIND.NS's competition here
NH.NS vs UNIHEALTH.NS Comparison April 2026
NH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NH.NS stands at 330B. In comparison, UNIHEALTH.NS has a market cap of 6.1B. Regarding current trading prices, NH.NS is priced at ₹1,625.00, while UNIHEALTH.NS trades at ₹393.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NH.NS currently has a P/E ratio of 42.47, whereas UNIHEALTH.NS's P/E ratio is 40.08. In terms of profitability, NH.NS's ROE is +0.21%, compared to UNIHEALTH.NS's ROE of N/A. Regarding short-term risk, NH.NS is less volatile compared to UNIHEALTH.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NH.NS.Check UNIHEALTH.NS's competition here
NH.NS vs ASARFI.BO Comparison April 2026
NH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NH.NS stands at 330B. In comparison, ASARFI.BO has a market cap of 3.6B. Regarding current trading prices, NH.NS is priced at ₹1,625.00, while ASARFI.BO trades at ₹180.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NH.NS currently has a P/E ratio of 42.47, whereas ASARFI.BO's P/E ratio is 21.78. In terms of profitability, NH.NS's ROE is +0.21%, compared to ASARFI.BO's ROE of +0.14%. Regarding short-term risk, NH.NS is less volatile compared to ASARFI.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NH.NS.Check ASARFI.BO's competition here
NH.NS vs LOTUSEYE.NS Comparison April 2026
NH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NH.NS stands at 330B. In comparison, LOTUSEYE.NS has a market cap of 2.1B. Regarding current trading prices, NH.NS is priced at ₹1,625.00, while LOTUSEYE.NS trades at ₹102.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NH.NS currently has a P/E ratio of 42.47, whereas LOTUSEYE.NS's P/E ratio is 320.34. In terms of profitability, NH.NS's ROE is +0.21%, compared to LOTUSEYE.NS's ROE of +0.01%. Regarding short-term risk, NH.NS is less volatile compared to LOTUSEYE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NH.NS.Check LOTUSEYE.NS's competition here
NH.NS vs LOTUSEYE.BO Comparison April 2026
NH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NH.NS stands at 330B. In comparison, LOTUSEYE.BO has a market cap of 2.1B. Regarding current trading prices, NH.NS is priced at ₹1,625.00, while LOTUSEYE.BO trades at ₹100.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NH.NS currently has a P/E ratio of 42.47, whereas LOTUSEYE.BO's P/E ratio is 314.53. In terms of profitability, NH.NS's ROE is +0.21%, compared to LOTUSEYE.BO's ROE of +0.01%. Regarding short-term risk, NH.NS is less volatile compared to LOTUSEYE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NH.NS.Check LOTUSEYE.BO's competition here
NH.NS vs MADHAVBAUG.NS Comparison April 2026
NH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NH.NS stands at 330B. In comparison, MADHAVBAUG.NS has a market cap of 2B. Regarding current trading prices, NH.NS is priced at ₹1,625.00, while MADHAVBAUG.NS trades at ₹191.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NH.NS currently has a P/E ratio of 42.47, whereas MADHAVBAUG.NS's P/E ratio is 24.71. In terms of profitability, NH.NS's ROE is +0.21%, compared to MADHAVBAUG.NS's ROE of N/A. Regarding short-term risk, NH.NS is less volatile compared to MADHAVBAUG.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NH.NS.Check MADHAVBAUG.NS's competition here
NH.NS vs LEHIL.BO Comparison April 2026
NH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NH.NS stands at 330B. In comparison, LEHIL.BO has a market cap of 1.9B. Regarding current trading prices, NH.NS is priced at ₹1,625.00, while LEHIL.BO trades at ₹89.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NH.NS currently has a P/E ratio of 42.47, whereas LEHIL.BO's P/E ratio is -315.00. In terms of profitability, NH.NS's ROE is +0.21%, compared to LEHIL.BO's ROE of +0.01%. Regarding short-term risk, NH.NS is less volatile compared to LEHIL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NH.NS.Check LEHIL.BO's competition here
NH.NS vs AASHKA.BO Comparison April 2026
NH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NH.NS stands at 330B. In comparison, AASHKA.BO has a market cap of 1.4B. Regarding current trading prices, NH.NS is priced at ₹1,625.00, while AASHKA.BO trades at ₹60.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NH.NS currently has a P/E ratio of 42.47, whereas AASHKA.BO's P/E ratio is 57.69. In terms of profitability, NH.NS's ROE is +0.21%, compared to AASHKA.BO's ROE of +0.02%. Regarding short-term risk, NH.NS is more volatile compared to AASHKA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NH.NS.Check AASHKA.BO's competition here
NH.NS vs JSTL.BO Comparison April 2026
NH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NH.NS stands at 330B. In comparison, JSTL.BO has a market cap of 1.1B. Regarding current trading prices, NH.NS is priced at ₹1,625.00, while JSTL.BO trades at ₹66.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NH.NS currently has a P/E ratio of 42.47, whereas JSTL.BO's P/E ratio is -52.43. In terms of profitability, NH.NS's ROE is +0.21%, compared to JSTL.BO's ROE of -0.06%. Regarding short-term risk, NH.NS is less volatile compared to JSTL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NH.NS.Check JSTL.BO's competition here
NH.NS vs MAITREYA.NS Comparison April 2026
NH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NH.NS stands at 330B. In comparison, MAITREYA.NS has a market cap of 998.9M. Regarding current trading prices, NH.NS is priced at ₹1,625.00, while MAITREYA.NS trades at ₹183.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NH.NS currently has a P/E ratio of 42.47, whereas MAITREYA.NS's P/E ratio is 28.56. In terms of profitability, NH.NS's ROE is +0.21%, compared to MAITREYA.NS's ROE of N/A. Regarding short-term risk, NH.NS is more volatile compared to MAITREYA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NH.NS.Check MAITREYA.NS's competition here
NH.NS vs FORTISMLR.BO Comparison April 2026
NH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NH.NS stands at 330B. In comparison, FORTISMLR.BO has a market cap of 876.6M. Regarding current trading prices, NH.NS is priced at ₹1,625.00, while FORTISMLR.BO trades at ₹46.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NH.NS currently has a P/E ratio of 42.47, whereas FORTISMLR.BO's P/E ratio is 19.33. In terms of profitability, NH.NS's ROE is +0.21%, compared to FORTISMLR.BO's ROE of +0.15%. Regarding short-term risk, NH.NS is less volatile compared to FORTISMLR.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NH.NS.Check FORTISMLR.BO's competition here
NH.NS vs ASPIRA.BO Comparison April 2026
NH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NH.NS stands at 330B. In comparison, ASPIRA.BO has a market cap of 597.7M. Regarding current trading prices, NH.NS is priced at ₹1,625.00, while ASPIRA.BO trades at ₹58.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NH.NS currently has a P/E ratio of 42.47, whereas ASPIRA.BO's P/E ratio is 42.08. In terms of profitability, NH.NS's ROE is +0.21%, compared to ASPIRA.BO's ROE of +0.11%. Regarding short-term risk, NH.NS is less volatile compared to ASPIRA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NH.NS.Check ASPIRA.BO's competition here
NH.NS vs SANGANI.NS Comparison April 2026
NH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NH.NS stands at 330B. In comparison, SANGANI.NS has a market cap of 537.3M. Regarding current trading prices, NH.NS is priced at ₹1,625.00, while SANGANI.NS trades at ₹39.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NH.NS currently has a P/E ratio of 42.47, whereas SANGANI.NS's P/E ratio is 20.74. In terms of profitability, NH.NS's ROE is +0.21%, compared to SANGANI.NS's ROE of N/A. Regarding short-term risk, NH.NS is more volatile compared to SANGANI.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NH.NS.Check SANGANI.NS's competition here
NH.NS vs AATMAJ.NS Comparison April 2026
NH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NH.NS stands at 330B. In comparison, AATMAJ.NS has a market cap of 437.3M. Regarding current trading prices, NH.NS is priced at ₹1,625.00, while AATMAJ.NS trades at ₹19.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NH.NS currently has a P/E ratio of 42.47, whereas AATMAJ.NS's P/E ratio is 49.62. In terms of profitability, NH.NS's ROE is +0.21%, compared to AATMAJ.NS's ROE of N/A. Regarding short-term risk, NH.NS is less volatile compared to AATMAJ.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NH.NS.Check AATMAJ.NS's competition here
NH.NS vs NGIND.BO Comparison April 2026
NH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NH.NS stands at 330B. In comparison, NGIND.BO has a market cap of 435.1M. Regarding current trading prices, NH.NS is priced at ₹1,625.00, while NGIND.BO trades at ₹129.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NH.NS currently has a P/E ratio of 42.47, whereas NGIND.BO's P/E ratio is -31.44. In terms of profitability, NH.NS's ROE is +0.21%, compared to NGIND.BO's ROE of -0.04%. Regarding short-term risk, NH.NS is more volatile compared to NGIND.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NH.NS.Check NGIND.BO's competition here
NH.NS vs MEDINOV.BO Comparison April 2026
NH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NH.NS stands at 330B. In comparison, MEDINOV.BO has a market cap of 433.7M. Regarding current trading prices, NH.NS is priced at ₹1,625.00, while MEDINOV.BO trades at ₹43.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NH.NS currently has a P/E ratio of 42.47, whereas MEDINOV.BO's P/E ratio is 20.21. In terms of profitability, NH.NS's ROE is +0.21%, compared to MEDINOV.BO's ROE of -1.80%. Regarding short-term risk, NH.NS is less volatile compared to MEDINOV.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NH.NS.Check MEDINOV.BO's competition here
NH.NS vs SML.BO Comparison April 2026
NH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NH.NS stands at 330B. In comparison, SML.BO has a market cap of 299.5M. Regarding current trading prices, NH.NS is priced at ₹1,625.00, while SML.BO trades at ₹70.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NH.NS currently has a P/E ratio of 42.47, whereas SML.BO's P/E ratio is -15.00. In terms of profitability, NH.NS's ROE is +0.21%, compared to SML.BO's ROE of -2.04%. Regarding short-term risk, NH.NS is less volatile compared to SML.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NH.NS.Check SML.BO's competition here
NH.NS vs TEJNAKSH.BO Comparison April 2026
NH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NH.NS stands at 330B. In comparison, TEJNAKSH.BO has a market cap of 259.6M. Regarding current trading prices, NH.NS is priced at ₹1,625.00, while TEJNAKSH.BO trades at ₹12.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NH.NS currently has a P/E ratio of 42.47, whereas TEJNAKSH.BO's P/E ratio is 18.79. In terms of profitability, NH.NS's ROE is +0.21%, compared to TEJNAKSH.BO's ROE of +0.05%. Regarding short-term risk, NH.NS is less volatile compared to TEJNAKSH.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NH.NS.Check TEJNAKSH.BO's competition here
NH.NS vs KKSHL.BO Comparison April 2026
NH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NH.NS stands at 330B. In comparison, KKSHL.BO has a market cap of 250.9M. Regarding current trading prices, NH.NS is priced at ₹1,625.00, while KKSHL.BO trades at ₹36.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NH.NS currently has a P/E ratio of 42.47, whereas KKSHL.BO's P/E ratio is -24.40. In terms of profitability, NH.NS's ROE is +0.21%, compared to KKSHL.BO's ROE of -0.02%. Regarding short-term risk, NH.NS is less volatile compared to KKSHL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NH.NS.Check KKSHL.BO's competition here
NH.NS vs CMMHOSP.BO Comparison April 2026
NH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NH.NS stands at 330B. In comparison, CMMHOSP.BO has a market cap of 249.6M. Regarding current trading prices, NH.NS is priced at ₹1,625.00, while CMMHOSP.BO trades at ₹33.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NH.NS currently has a P/E ratio of 42.47, whereas CMMHOSP.BO's P/E ratio is -32.13. In terms of profitability, NH.NS's ROE is +0.21%, compared to CMMHOSP.BO's ROE of +0.42%. Regarding short-term risk, NH.NS is less volatile compared to CMMHOSP.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NH.NS.Check CMMHOSP.BO's competition here
NH.NS vs NIDAN.NS Comparison April 2026
NH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NH.NS stands at 330B. In comparison, NIDAN.NS has a market cap of 193.2M. Regarding current trading prices, NH.NS is priced at ₹1,625.00, while NIDAN.NS trades at ₹13.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NH.NS currently has a P/E ratio of 42.47, whereas NIDAN.NS's P/E ratio is 9.79. In terms of profitability, NH.NS's ROE is +0.21%, compared to NIDAN.NS's ROE of N/A. Regarding short-term risk, NH.NS is more volatile compared to NIDAN.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NH.NS.Check NIDAN.NS's competition here
NH.NS vs FAMILYCARE.BO Comparison April 2026
NH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NH.NS stands at 330B. In comparison, FAMILYCARE.BO has a market cap of 150.7M. Regarding current trading prices, NH.NS is priced at ₹1,625.00, while FAMILYCARE.BO trades at ₹2.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NH.NS currently has a P/E ratio of 42.47, whereas FAMILYCARE.BO's P/E ratio is -2.88. In terms of profitability, NH.NS's ROE is +0.21%, compared to FAMILYCARE.BO's ROE of -0.43%. Regarding short-term risk, NH.NS is less volatile compared to FAMILYCARE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NH.NS.Check FAMILYCARE.BO's competition here
NH.NS vs GLHRL.BO Comparison April 2026
NH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NH.NS stands at 330B. In comparison, GLHRL.BO has a market cap of 148.6M. Regarding current trading prices, NH.NS is priced at ₹1,625.00, while GLHRL.BO trades at ₹14.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NH.NS currently has a P/E ratio of 42.47, whereas GLHRL.BO's P/E ratio is -6.29. In terms of profitability, NH.NS's ROE is +0.21%, compared to GLHRL.BO's ROE of +0.01%. Regarding short-term risk, NH.NS is less volatile compared to GLHRL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NH.NS.Check GLHRL.BO's competition here
NH.NS vs ZDHJERK.BO Comparison April 2026
NH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NH.NS stands at 330B. In comparison, ZDHJERK.BO has a market cap of 110.2M. Regarding current trading prices, NH.NS is priced at ₹1,625.00, while ZDHJERK.BO trades at ₹26.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NH.NS currently has a P/E ratio of 42.47, whereas ZDHJERK.BO's P/E ratio is 89.67. In terms of profitability, NH.NS's ROE is +0.21%, compared to ZDHJERK.BO's ROE of +0.01%. Regarding short-term risk, NH.NS is more volatile compared to ZDHJERK.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NH.NS.Check ZDHJERK.BO's competition here
NH.NS vs GIANLIFE.BO Comparison April 2026
NH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NH.NS stands at 330B. In comparison, GIANLIFE.BO has a market cap of 67.1M. Regarding current trading prices, NH.NS is priced at ₹1,625.00, while GIANLIFE.BO trades at ₹6.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NH.NS currently has a P/E ratio of 42.47, whereas GIANLIFE.BO's P/E ratio is -6.90. In terms of profitability, NH.NS's ROE is +0.21%, compared to GIANLIFE.BO's ROE of -0.05%. Regarding short-term risk, NH.NS is less volatile compared to GIANLIFE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NH.NS.Check GIANLIFE.BO's competition here
NH.NS vs DLCL.BO Comparison April 2026
NH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NH.NS stands at 330B. In comparison, DLCL.BO has a market cap of 64.2M. Regarding current trading prices, NH.NS is priced at ₹1,625.00, while DLCL.BO trades at ₹14.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NH.NS currently has a P/E ratio of 42.47, whereas DLCL.BO's P/E ratio is 19.23. In terms of profitability, NH.NS's ROE is +0.21%, compared to DLCL.BO's ROE of +0.04%. Regarding short-term risk, NH.NS is more volatile compared to DLCL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NH.NS.Check DLCL.BO's competition here
NH.NS vs LOOKS.BO Comparison April 2026
NH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NH.NS stands at 330B. In comparison, LOOKS.BO has a market cap of 62.9M. Regarding current trading prices, NH.NS is priced at ₹1,625.00, while LOOKS.BO trades at ₹5.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NH.NS currently has a P/E ratio of 42.47, whereas LOOKS.BO's P/E ratio is 29.95. In terms of profitability, NH.NS's ROE is +0.21%, compared to LOOKS.BO's ROE of +0.01%. Regarding short-term risk, NH.NS is more volatile compared to LOOKS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NH.NS.Check LOOKS.BO's competition here
NH.NS vs NEPHROCARE-ST.NS Comparison April 2026
NH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NH.NS stands at 330B. In comparison, NEPHROCARE-ST.NS has a market cap of 0. Regarding current trading prices, NH.NS is priced at ₹1,625.00, while NEPHROCARE-ST.NS trades at ₹128.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NH.NS currently has a P/E ratio of 42.47, whereas NEPHROCARE-ST.NS's P/E ratio is N/A. In terms of profitability, NH.NS's ROE is +0.21%, compared to NEPHROCARE-ST.NS's ROE of N/A. Regarding short-term risk, NH.NS is more volatile compared to NEPHROCARE-ST.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NH.NS.Check NEPHROCARE-ST.NS's competition here